Pharmaceutical Companies Focus on Novel Therapeutics for Chemotherapy-Induced Myelosuppression Treatment

Although chemotherapy is amongst the few treatments for cancer, there are numerous side effects associated with therapy. Chemotherapy-induced myelosuppression is one such common complication of cancer treatment that could not only limit dosage but also prove potentially fatal for cancer patients. Chemotherapy-induced myelosuppression is a condition wherein the ability of the bone marrow to produce blood cells is decreased. There have been various attempts to minimize chemotherapy-induced myelosuppression, which have not been very effective. This has triggered the need for innovating and developing more effective chemotherapy-induced myelosuppression treatment. Pharmaceutical companies are working towards bringing new therapeutics that could help in boosting the capabilities in the chemotherapy-induced myelosuppression treatment.

New Investments Aimed at Addressing Chemotherapy-Induced Myelosuppression Treatment Requirements

While cancer reflects growth, the chemotherapy-induced myelosuppression conditions are also expected to come along with the cancer therapeutics, thereby creating need for effective chemotherapy-induced myelosuppression treatment. Investments remain a crucial factor that helps boost the chemotherapy-induced myelosuppression treatment. For instance, a recognized developer of off-the-shelf and universal cell therapies for critical diseases, Nohla Therapeutics closed a Series B financing of about $45 million. The company plans to utilize the proceeds for the completion of the ongoing Phase 2 trials of the dilanubicel, which is a major candidate in chemotherapy-induced myelosuppression and allogeneic transplant. Moreover, these proceedings are intended to be used for the commercial manufacturing and Phase 3 trial needs. It would allow Nohla Therapeutics to contribute their ongoing progress in advancing their product, dilanubicel towards potential regulatory approvals in several regions. Such investments are expected to boost the chemotherapy-induced myelosuppression treatment potential across the globe.

Pharmaceutical Companies Bullish over New Therapeutics

The pharmaceutical companies conduct various trials that help gauge the efficacy of certain drugs for the chemotherapy-induced myelosuppression treatment. With several developments hitting the chemotherapy-induced myelosuppression treatment landscape with respect to the clinical trials, the pharmaceutical companies are gaining major profitability over time.

For instance, Trilaciclib by G1 Therapeutics, a biopharmaceutical company, is a chemotherapy-induced myelosuppression treatment which appeared to reduce chemotherapy-induced myelosuppression in small cell lung cancer. During the clinical trials, it was witnessed that the cancer patients undergoing first-line therapy for extensive-stage small cell lung cancer could well tolerate trilaciclib. The clinical trial data demonstrated clear evidence that this chemotherapy-induced myelosuppression treatment could help in preserving the immune system function and bone marrow from the side effects of chemotherapy. With positive myelopreservation results gained from two randomized trials, the company plans to request meetings with regulatory agencies of the US and Europe in early 2019 to discuss the factors studies during clinical trials and the potential approval for their treatment.

Adjuvant Therapy for Cancer Management to Gain Popularity

Adjuvant cancer therapies are used to enhance and foster the effect of primary cancer therapies in eliminating or minimizing the burden of cancer on the body, thereby help prevent cancer recurrence and boost survival of patients. Adjuvant therapy is gaining major significance in cancer management. In line with this, there are several new therapies introduced that are further gaining a nod from regulatory bodies, simplifying chemotherapy-induced myelosuppression treatment. For instance, Myelo Therapeutics GmbH, a leading pharmaceutical company that develops innovative therapeutics for chemotherapy-induced myelosuppression treatment and others, was recently granted an Organ Drug Designation from the US FDA for its new chemical offering, Myelo001, designed to treat Acute Radiation Syndrome. Myelo001 is a revolutionary and clinical-stage adjuvant cancer therapy for the radiotherapy- and chemotherapy-induced myelosuppression treatment. With this FDA approval, Myelo Therapeutics is able to open new possibilities in the chemotherapy-induced myelosuppression treatment landscape, with respect to adjuvant therapy.

The ongoing research and development in chemotherapy-induced myelosuppression treatment are expected to trigger new innovations over the years. To know more about the key developments carried out by pharmaceutical companies providing chemotherapy-induced myelosuppression treatment, click here.

Processing Technology Innovations to Drive the Production of Pyrolysis Gasoline (Pygas)

Found as a by-product during the high temperature production of ethylene and propylene, the colorless pygas (pyrolysis gasoline) is a great source of octane and aromatics, which has made it a key additive in modern automobile fuels. Alternatively, pygas may also be separated into its individual components such as xylene, toluene, and benzene. Its relatively higher unit value in comparison to conventional naphta is one of the key drivers that encourages businesses to produce and sell this material.

Manufacturers Invest in Research & Development Initiatives for Innovative Production Techniques

Innovative technologies in production and processing pyrolysis gasoline is anticipated to provide lucrative opportunities to manufacturers, owing to the increased use of octane compounds in motor fuels, and its use as a source for fuel oil products.

For example, GTC Technology LLC of the United States makes use of an innovative 2-step, hydro treating procedure, which allows for improved saturation of styrene, olefins, and di-olefins, through a preheating process of pygas feed stream along with hydrogen, which allows producers to achieve higher flexibility in the cut point of prefractionators, and the potential of polymerization. The process also minimizes the plugging of polymer byproducts and vaporization of hydrocarbons, and simultaneously improves on aspects such as the run length of the reactor, higher stability, resistance to poison, and heat integration, among others.

Shell has also revealed details on its use of CRI catalyst, to build on the reliability of the hydrogenation of pyrolysis gasoline, which is an effective solution to the problems faced while processing highly reactive pygas. Short cycles of reactor activity, increased polymerization, and pressure drops that increase the chances of fouling.  The hydrogenation process optimizes the characteristics of the feed, and the utilization of catalysts and grading, which claims to reach or exceed the production targets, when implemented correctly.

Similarly the SK Corporation patented their process of extracting BTX aromatics and other value-added components through a unique catalytic hydrodealkylation procedure that extracts the components of stabilized pygas through the resultant low ethyl-benzene mixture of BTX, LPG, and fuel gas.

Manufacturers Shifting Pygas Production from Naphtha to Ethane Feedstock

Pygas manufacturers are constantly facing challenges in maintaining their operations despite frequent fluctuations in the price of raw materials that are needed for the pyrolysis gasoline procedure. This is a key factor that is anticipated to restrict the market in the near future. To counter this issue, manufacturers are increasingly adopting alternative raw materials such as ethane to replace the conventional resources of naphtha in their operations.

A recent study by Chem Systems Ltd. found that the extraction of ethane from associated gases is one of the most cost-effective ways of extracting ethylene, and other byproducts. This is anticipated to sustain a steady growth of pygas producers in the near future.

The demand for such blends is anticipated to be influenced by factors such as unusually strict access to oil reserves, increasing production capacities, GDP, and utilization rates among others.

Design Innovations in Steam Crackers to Improve Production Processes

Steam crackers are frequently used equipment in the process of pyrolysis gasoline production, with innovations in design, production of pygas is anticipated to see better prospects in the near future. For example, Kellogg Brown and Root LLC in collaboration with SK Innovation Global Technology has created steam crackers with their Advanced Catalytic Olefins technology that is able to extract higher amounts of ethylene and propylene, by up to 25% , at lower energy consumption.

On a similar note Exxon Mobil patented a steam cracker with a unique fluid solids naphtha cracking process, which is dependent on reactor design, catalyst optimization, and operating conditions that allows adjustment in the selectivity of reactions, which provides manufacturers significant economic benefits in comparison to conventional processes.

To know more? Download sample copy of this report.

Aimed at Firming Up Sales Volume, Cox Automotive to Expand its Business Network

Cox Automotive is all set to reinvigorate its UK network of Manheim auction centers, which will include fewer yet bigger sites to foster the surging sales volume online.

At present, the company owns 16 discrete physical sites, which is anticipated to shrink in terms of number over the next few years in line with the evolution of larger sites offering a wide array of reconditioning as well as logistical hand over services.

As per Martin Forbes, CEO of Cox Automotive told, the count of sites would come down but the overall acreage would scale up as the drive gains momentum online.

The company is vying to expand its business framework to digital lines. This also means that company is definitely penetrating largely into vehicle-service, storage, transport, and de-fleeting services, which will be immensely instrumental to keep the organization future proof and profitable.

The firm has its utmost focus on the market of wholesale business-to-business. The company also sheds light on the big-time realization of the fact that demand in case of physical auction lanes will decelerate and a shift toward online channels will be induced, as conveyed by prospering online sales figures. In this case, the company strives to be keep up with the evolving trends to keep their business footprint strong than ever. 

Highlights by Forbes on which direction the market is heading toward included examples of automakers disposing of new stock and ex-company cars via closed auctions. Many of the prominent OEMs believe that by 2023, around more than half of their wholesale used stock would be sold online and this belief relies on evolving facts and figures indicated by the recent trends.

Though the number of sites will be few, these sites will be extremely beneficial in terms of more acerage and will also provide you enough room for offering satisfactory services at the cost of minimum inconvenience.

The transformation of the auto business i.e. selling cars and trucks is flourishing at a meteoric pace like never before, comes along some new promises in terms of changes as an industry that has been long famed for high cost factor, unsatisfactory services, and so on. Auto manufacturers have landed on the grounds for a fierce competition in terms of driving out cost and rolling out offerings tailored to evolving consumer expectations and specifications. Apart from the online sales channels, some other channels have also gained notable prominence in terms of sales and decision-making.

Governmental Policy Shift Along with Changing Landscape Threatens Chinese Drug maker’s Generic-based Business Model

Chinese drug maker’s stocks plunged by $46 billion in December 2018.  Chinese government is planning a shift in its drug pricing policy by undertaking bulk procurement of drugs as part of its new program. The move is significant as it will bring down prices of drugs as a major step towards universal and cheaper access of drugs to its citizens.

Generic drugs are a class of drugs whose patents have been expired, Chinese domestic pharmaceutical industry relied mostly on manufacturing generic drugs. After serving inflated profit margins to the industry, governmental policy shift has raised concerns about the efficacy of generic drugs profitability in the long run.

The central procurement program of drugs launched by Chinese government buys drugs for a city in bulk, as contracts are placed in competitive bids by pharmaceutical companies the prices of drugs have fallen forcing the fragmented industry into consolidation. This is only the beginning as the government plans to expand the program to all major cities in near future. One such bidding, drove down the price of the drugs by 55% and the other by as much as 90%. This radical shift in governmental policy has forced pharmaceutical companies into introspecting its business model.

According to fresh data gathered by Bloomberg, of the top 100 generic drug makers, Chinese companies with a gross and profit margin of 74% and 18% respectively, outran the global average of 55% and 9.5%.  The oversized profit margins owe their existence to regulatory privileges enjoyed by many. The domestic generic drug makers swiftly acquired government approval for copying drugs, while foreign multinationals had to wait for years to get government’s green signal. This along with the absence of any regulatory quality control gave domestic companies to rapidly expand in the market.  

But now many companies are planning to reverse this overdependence on generic drugs driven business model by investing more on Research and Development. The new landscape will favor companies who have already invested heavily in R&D. The companies with impressive R&D investment are Jiangsu Hengrui Medicine, Yipinhong Pharmaceutical and Chengdu Kanghong Pharmaceuticals with 16%, 8.4% and 8% of R&D investment of their total revenues respectively. Jiangsu Hengrui has 20:80 novel to generic drugs revenue ratio, the company wants invert this by focusing on new research.

Launching any novel drug is a many-year-long process, Chinese pharmaceuticals will find it hard to compete with global giants with vast talent pool and deep pockets. However, experts believe that with generic drugs revenue in shock, the transition to R&D and novel drugs won’t be easy.

Colpac to Launch Recyclable and Compostable Heat Seal Sandwich Pack, Aims to Build Consumer Confidence with Environmentally-Responsible Offerings

Sustainability is no longer just a trend, rather it has become more of a necessity. Many of the big brands are coming forward and taking significant steps in this direction to make their offerings in line with the necessities of sustainability. Similarly, Colpac is set to launch a latest and exclusive product from its Zest eco packaging range at Packaging Innovations i.e. a recyclable and compostable heat seal sandwich pack.

The company stated that this particular launch of heat seal packaging has the potential to aid in extending shelf life of the food inside having short-life ingredients and is ecofriendly by nature.

The pack, along with the window, has been created using recyclable materials, such as paperboard, that enable the complete pack to get instantly recycled. Appropriate for any sort of food service operators, ranging from delicatessens to bakeries and from restaurants to supermarkets, the pack offers feasibility in terms of customization to a large extent as per the user specifications.

The eco packaging format by Colpac was developed as a response to the mushrooming demand from various food service establishments and operators, who are on a lookout for packaging, which is compatible with various steams of waste.

Packaging Innovations shall be conducted at NEC Birmingham from 27th February onwards. With rising consumer preferences for products offered by sustainable companies, leading brands are paying immense attention to offer products that are environmentally responsible. For years it has been claimed that consumers are not concerned with products being environmentally-responsible, which is not the case anymore. It’s increasingly observed that sales figures of products that are environmentally responsible have crossed significant boundaries as compared to that of the ones that are not environmentally responsible. The aforementioned has been inferred in line with statistics from some of the world’s leading organizations. With drastic changes in climatic adversities, damage to environment has become uncompromising and larger brands with stronghold are not willing to take risks in terms of customer confidence on their products. Unmet consumer needs do exist across many categories, with packaging being a prominent one. This step by Colpac in terms of aligning their production strategies vis-à-vis sustainability and launching products along the similar lines will definitely help the company tap into some colossal business opportunities and gain high-profit margins.

Australian Oil Explorer Melbana Finalizes Agreement with Chinese Major to Drill Three Wells in Cuba’s Block 9

Australian oil explorer Melbana Energy has signed agreement with Anhui Modestinner Energy, a subsidiary of Chinese major Anhui Guangda Mining Investment to conduct drilling operations in exploration well Alameda1 in northern Cuba.

Alameda is highest ranking exploration target in block 9, and holds a structural proximity to the largest oil field in Cuba, Varadero field, which is nearly 35 km away. Block 9 is one the most underexplored onshore acreage covers around 2,380 Sq. Km.  Three wells are planned to be drilled in this key location.

This is a recent development after a letter of intent was formulated in October last year mutually by both parties. The farm-out agreement is legally binding on both parties. Anhui Modestinner is an international equipment and oilfield service provider. Melbana CEO Robert Zammit, believes the prospects are high for Alameda1 exploration, Alameda and Zapato drills will come with zero cost to company.

The terms of the farm-out agreement state that Anhui will fund all costs of block 9 production, including the three wells. The two wells at Zapato and Alameda will be drilled by November 2019 and the third by July 2020. Anhui will provide all necessary guarantees to the Australian oil explorer along with 12.5% profit sharing. Melbana will cover back costs of $3.5 million for Block 9. The conditions of the agreement includes securing Chinese and Cuban regulatory approvals.

Melbana in December 2018 signed a long term binding contract to share any enhanced production from Santa Cruz oil field with CubaPetrolio. The Santa Cruz field has a potential of 100 million barrels of recoverable oil. The field is offshore, just 28 Miles away from Havana. The Beehive prospect along with Alameda exploration will significantly improve Melbana’s growth prospects.

According to preliminary reports from USEIA, Cuba is heavily dependent on imports with imports of 1, 72,000 barrels per day and domestic production of about 50,000 barrels per day. The area offers significant potential as it was left unexplored by the American 60-year embargo during cold war. In 2016, Cuban oil assets were estimated at 124 million barrels. With Melbana drills the country is set to harness the immense underexploited oil and gas potential which will help reduce its imports.

Bristol-Myers Agrees on Acquisition of Celgene; Healthcare ETFs Remains the Key Focus

The healthcare industry has been continually witnessing a wave of strategic mergers and acquisitions, which could bring in major transformations in the spectrum of healthcare business. Post multiple series of consolidation between the pharmacy benefits managers and health insurers last year, biotech companies have been flourishing in the healthcare space as they have evolved as highly attractive targets for large firms after their valuations came down in the past few months.

This is apparently evident as Bristol-Myers Squibb, a leading American pharmaceutical company, agreed vis-à-vis acquiring Celgene Corporation for a valuation worth $74 billion, in terms of cash and stock deal. This proposed deal would be beneficial for either of the companies that are struggling in the cancer market (presently one of the largest pharmaceutical spaces) for innovation-oriented treatments.

Details of the Deal

As per terms and conditions of the deal, Celgene investors would be receiving one Bristol-Myers share and around $50 cash for every holding of Celgene, along with a contingent value of $9, in case three treatments in development get approvals at the right time.

The deal values Celgene at $102.43 each, a premium of around 53.7% to the closing price and would bring in together two of the global leaders in cancer drug businesses in the largest ever pharmaceutical deal. The combined company would be 69% taken by Bristol-Myers and will frame a specialty biopharma company dedicated for treatments in cancer, inflammatory, and cardiovascular diseases. It will also have a robust portfolio of around nine drugs with a surpassed valuation of $1 billion in case of annual sales.

The transaction would eventually translate into an overall cost savings of around $2.5 billion by 2022, with around 55% derived from cuts in expenses in terms of  general, sales, and administrative, 35% via reduction in the research & development spending and around 10% from the manufacturing spectrum. Therefore, Bristol-Myers anticipates the deal to supplement 40% to its net earnings in the first year post closing.

The news has shed some light on multiple number of ETFs in healthcare, primarily in case of biotech and pharma, which could be in absolute favor of investors to leverage opportunity coming from the BMY-CELG deal. Investors should also keep a close track of the movement of ETFs in the forthcoming weeks.

In multiple cases, acquisitions are instrumental in terms of overcoming significant hindrances in achieving organic growth or growth obtained with the help of the existing assets. Otherwise, in case the existing business is not growing in significant terms, purchasing another business has become more of a common strategy to flourish and reap significant benefits through augmented cash flow.

Graphene based Implant will Deepen the Understanding of Brain at Low Frequencies

Researchers in Barcelona have found a new grapheme based implant to map the brains activity below 0.1 Hz of frequency. The prototype created at Barcelona Microelectronics Institute will help in understanding the brains activity exponentially.

For decades researchers were using electrode arrays to map the activity in the various parts of the brain. The electrode arrays were helpful in understanding which areas of the brain are active when a particular activity was being performed and which areas were silent. But a limitation to this technology was that this could only detect frequencies over certain threshold. This limited the scope of understanding brains working at subtle frequencies. The new technology has paved the way for understanding brains working below the frequency of 0.1 Hz.

The technology was invented as a collaboration project involving Barcelona Microelectronics Institute, CIBER in Bioengineering, Catalan Institute of Nano sciences and Nanotechnology, August Pi i Sunyer Biomedical Research Institute. The Technology by using a transistor based architecture amplifies low frequencies before they are transmitted to the receiver, this technology will do away the existing electrode array method of brain’s activity mapping.

Graphene being flexible and slim will enable the use of implants in various parts of brain earlier unexplored by the electrode array method of mapping. Information on Many new regions of brain will be available by this technology’s application. For neurologists this is good news as hearing and understanding subtle whispers of the brain will be possible for the first time with the new technology. Unprecedented insights are awaited by academia and researchers alike on such matters like the origins of seizure and effective diagnosis and treatment for conditions like epilepsy by the full throttle application of this technology.

The technique where a large number are recording sites are explored by using transistor configuration is called multiplexing strategy. A European project BrainCom, is using the same technique to restore communication and speech in patients. The project is working on creating new array of brain-computer interfaces to repair high level of cognitive functions focusing particularly on speech disorders caused by spinal cord or brain injuries.

Graphene has shown promising applications in medical implants field, with news reports in April 2018 breakthrough innovation where vertical; grapheme could be used to kill bacteria while surgery and stop further infection. When the flakes were added to the surface of the implant Graphene hindered bacterial infection during the surgery. This and other interesting applications of Graphene has shown promising future for nanotechnology applications in medicine and medical implants.

Medical Manufacturers are Exploiting a Grandfathering Clause in the Regulation to Postpone Implementation of EU’s New Rules

As Implant Files, an investigation by International Consortium of Investigative Journalists (ICIJ), have exposed failure of medical regulators to test faulty medical implants and save lives, companies are using an exemption clause to escape from EU’s new rules. The May 2020 Deadline for manufacturers who test medical devices to comply with recertification norms has led many companies to look for loopholes in the law.

EU instead of making new regulation is opting for stricter compliance of norms in the existing law.

ICIJ’s Implant files reported 4400 violations by device companies to report complaints and device problems in the last decade, the outrage ran across all sections of public opinion.

Companies are exploiting a grandfathering clause in the law to postpone recertification for another five years. European commission stated that the intention for the clause was to apply under some very specific conditions so that key products which could not make it up to the deadline wouldn’t have to be taken off the shelf. A clause which was meant to be a safe exit or a Plan B is being used by medical manufacturers to bypass implementation deadline.

The postponement of recertification will result in delay in access to critical medical devices to patients.   The grace period clause which allows companies to postpone recertification up to 2025 will not be feasible for the safety of patient as well as by transparency perspective, according to a senior member of EPF, A nodal patient advocacy group in Europe.

The Delay seems deliberate as MedTech, a lobbying firm for device makers warned of large scale discontinuation of vital medical technology products the healthcare industry has relied on for decades. In May 2018, just two years away from deadline, the firm replied with a negative response on whether recertification was on track. Concerned voices in European Parliament have shown skepticism about the new framework’s ability to effectively ensure compliance.

The medical device industry has around 27,000 players which collectively make 5, 00,000 products. Around a handful of 60 bodies which have been notified, has gained final approval from European commission to scrutinize and certify medical products according to safety standards. The regulation attracted criticism as the bodies which appointed certification are themselves waiting for final approval. The administrative lapses along with escapist attitude of companies has enraged patient rights and advocacy groups all over the continent.

Spain and Denmark seems to have taken the issue seriously and it was put on immediate agenda on Health Council in December last year. The commission having worked for decades to formulate these norms, can’t wait for another delay in its implementation, said Ellen Trane Norby, the Danish Health Minister.

Antioxidants in Grain Bran Shows Potential for Naturally Preserving Food says Penn State Researchers

Food preservatives have shown a tendency to cause allergic reactions and have proved to be less than ideal for our health. Researchers from Pennsylvania State University have found a natural antioxidant in grain bran which has shown potential to be used for food preservation in the coming years. Grain bran is the hard cover of grain.

Antioxidants are compounds responsible for slowing down the degradation rate of omega-3 fatty acids. Omega-3 fatty acids with lots of health benefits, for many years is being added to healthy foods. Antioxidants preserve the health benefits of these acids by slowing down their decay. A class of antioxidants called alkylresorcinols (AR) were studied by the Penn’s researchers which are naturally occurring compounds present in whole grains like rye, wheat and barley to prevent bacteria, mold and other organisms from growing on the grain kernels.

Food has very limited shelf life, which makes food preservatives an inevitable necessity for preserving foods for delayed consumption. Common food preservatives like nitrates and sulfites have shown numerous side effects including headache, nausea, allergies and palpitations. Some preservatives have been classified as probable cancer causing agents. Food industry have even fantasized using nuclear radiation for preserving food. The industry’s struggle to find natural antioxidants for preserving food in place of synthetic ones may be coming to an end with ARs.

ARs if used in preservation will make them ideal natural preservatives as they have many health benefits including helping to protect against cancer. Also ARs which come from bran layer of cereal grain, are very cost effective as gray bran is only used as animal fodder. Its use could be extended further by recycling.

Researchers extracted ARs from rye bran and used it in testing emulsion. As many people use oils as emulsions. Researchers found that the AR’s did work as antioxidants in preserving omega-3 fatty acids. The AR’s action was compared to two traditional antioxidants one natural and the other synthetic, namely Vitamin E and butylated hydroxytoluene respectively.

The research unfortunately showed that the AR’s did not prove to be as good as either the natural or synthetic antioxidants. They think the reason for the poor performance of AR may be that the ARs were not pure enough which may have reduced its activity. Now the researchers are testing the activity of ARs from different sources with different molecular structures. They are looking for a specific type of AR which will prove more effective than the conventional synthetic antioxidants.